Regeneron Pharmaceuticals REGN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Other products | $41.4M+310% | $10.1M+1,163% | $800K— | $0— | —— | |
| (Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, net | -$70.8M-1.7% | -$69.6M-1.9% | -$68.3M-29.8% | -$52.6M-20.4% | -$43.7M+6.6% | |
| Reimbursement For Manufacturing Of Commercial Supplies | $631.6M-1.7% | $642.3M-2.3% | $657.7M-2.0% | $671.3M+0.6% | $667.1M+9.7% | |
| Reimbursement Of Commercialization Related Expenses | $754.2M+3.4% | $729.3M-0.4% | $731.9M+1.9% | $718.3M+6.4% | $675.1M+3.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Regeneron Pharmaceuticals break its business down?
- Regeneron Pharmaceuticals (REGN) reports revenue by product across 5 parts — Lynozyfic, Other products, (Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, net, Reimbursement For Manufacturing Of Commercial Supplies and Reimbursement Of Commercialization Related Expenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Regeneron Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Regeneron Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
